RepliCel Life Sciences (TSXV:RP) EV-to-Revenue : 3.16 (As of Apr. 28, 2025)

View and export this data going back to 2012. Start your Free Trial

What is RepliCel Life Sciences EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, RepliCel Life Sciences's enterprise value is C$1.11 Mil. RepliCel Life Sciences's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was C$0.35 Mil. Therefore, RepliCel Life Sciences's EV-to-Revenue for today is 3.16.

The historical rank and industry rank for RepliCel Life Sciences's EV-to-Revenue or its related term are showing as below:

TSXV:RP's EV-to-Revenue is not ranked ^*
in the Biotechnology industry.
Industry Median: 6.845
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-04-28), RepliCel Life Sciences's stock price is C$0.015. RepliCel Life Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was C$0.01. Therefore, RepliCel Life Sciences's PS Ratio for today is 2.50.

RepliCel Life Sciences EV-to-Revenue Historical Data

The historical data trend for RepliCel Life Sciences's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RepliCel Life Sciences EV-to-Revenue Chart

RepliCel Life Sciences Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EV-to-Revenue

Get a 7-Day Free Trial

44.63

20.63

21.85

22.14

10.33

RepliCel Life Sciences Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EV-to-Revenue	Get a 7-Day Free Trial															11.38	10.33	25.84	31.77	22.19

Competitive Comparison of RepliCel Life Sciences's EV-to-Revenue

For the Biotechnology subindustry, RepliCel Life Sciences's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RepliCel Life Sciences's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RepliCel Life Sciences's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where RepliCel Life Sciences's EV-to-Revenue falls into.

Save Embed

;

Save Embed

;

RepliCel Life Sciences EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

RepliCel Life Sciences's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	1.112	/	0.352
	=	3.16

RepliCel Life Sciences's current Enterprise Value is C$1.11 Mil.
RepliCel Life Sciences's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.35 Mil.

RepliCel Life Sciences (TSXV:RP) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

RepliCel Life Sciences's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	0.015	/	0.006
	=	2.50

RepliCel Life Sciences's share price for today is C$0.015.
RepliCel Life Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.01.

RepliCel Life Sciences EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of RepliCel Life Sciences's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

RepliCel Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RepliCel Life Sciences Inc (TSXV:RP) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

570 Granville Street, Suite 900, Vancouver, BC, CAN, V6C 3P1

Website

https://www.replicel.com

RepliCel Life Sciences Inc is a Canadian regenerative medicine company. It focuses on developing autologous cell therapies that treat functional cellular deficits. The company addresses various diseases such as chronic tendon injuries, androgenetic alopecia, and skin aging. Its development program of the company is based on distinct technology that utilizes cells isolated from a patient's healthy hair follicles. Also, the company develops a programmable cell injector device designed for dermal injections of cells, dermal filler products, and a variety of other products injected through the skin. The treatments delivered by the company use autologous cell therapy which is developed for the treatment of androgenetic alopecia. The revenue is generated from the Licensing fees.

Executives